-
From Evidence to Enforcement? Implications of the 2025 SVR Report for Pharmaceutical Pricing and Orphan Drug Policy in Germany
Sep 9, 2025, 16:22 PM -
Real-World Cancer Treatments for Common Solid Tumors in China: A Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Live Attenuated Influenza Vaccination (LAIV) for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis
Sep 9, 2025, 16:22 PM -
Canadian HTA Decisions (2020-2023): Comparing CDA-AMC and INESSS Recommendations on Drug Reimbursement
Sep 9, 2025, 16:22 PM -
Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection
Sep 9, 2025, 16:22 PM -
Quantifying the Value of Information in Early Stage Health Technology Assessment: Guiding Investment in Evidence Generation
Sep 9, 2025, 16:22 PM -
Evolution of MRD in Hemato-Oncology Clinical Development
Sep 9, 2025, 16:22 PM -
Mapping the Measurement Gap: Patient-Reported Outcomes Across the Obesity Care Continuum in the GLP-1 Era
Sep 9, 2025, 16:22 PM -
HTA Readiness for Tumor-Agnostic Therapies: Lessons From Analogues Across Major Markets
Sep 9, 2025, 16:22 PM -
Does Proposed IRP Introduction in the US Align With Current IRP Trends and With Best Practice Guidelines?
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness
Sep 9, 2025, 16:22 PM -
Systematic Literature Review (SLR) of Efficacy, Health-Related Quality of Life (HRQoL), and Safety of the First-Line (1L) Treatments of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 9, 2025, 16:22 PM -
Clinical Benefit vs. Reimbursement Decisions: Examining Misalignments Between ESMO-MCBS and HTA Outcomes in Oncology
Sep 9, 2025, 16:22 PM -
The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Squamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye
Sep 9, 2025, 16:22 PM -
Economics of Improved Time in Range in Type 1 Diabetes Management in Italy, Spain, Greece, and Israel
Sep 9, 2025, 16:22 PM -
Patient-Reported Outcomes Used for Regulatory Approval of Oncology Medicinal Products in the European Union Between 2021 and 2024: A Review Update
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria
Sep 9, 2025, 16:22 PM -
Development of Two Versions of a Patient-Preference Questionnaire for Evaluating Potential HIV Cure-Related and Other HIV Interventions
Sep 9, 2025, 16:22 PM -
How Societal Is Sweden? A Study of Inclusion of Societal Costs in Swedish Reimbursement Decisions
Sep 9, 2025, 16:22 PM -
The Association Between COVID-19 Vaccination and the Healthcare Resource Use Related to COVID-19 in Typical Rural Residents in Japan
Sep 9, 2025, 16:22 PM
